The tech is being used to crunch thousands of documents in billion-dollar mediations and emerging as a valuable party at the ...

As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences ...

A panel of experts at LSPN shared how AI is forcing companies to rethink everything from obviousness arguments to the choice ...

Experts at LSPN North America Fall explore the often-overlooked factors that can make or break transactions, from employee ...

Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, ...

8 October 2025 A 2021 Supreme Court ruling changed how patent terms are calculated, forcing pharma companies to rethink their ...

Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ...

Just weeks into his tenure, USPTO director John Squires is blitzing US patent policy by taking control of how and when patent challenges can be brought, with proposed rules that could sharply limit ...

Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ...

Hire brings trade secrets and AI litigation expertise from Cooley as firm adds 14th US litigation partner this year. If you ...

Isomorphic Labs' head of IP shares why the first wave of AI-driven drug development stumbled, how data became pharma's most ...

The Japanese pharmaceutical company has filed a cluster of lawsuits against generic drug makers asserting its patent protection and market exclusivity over the high-selling ALS treatment. If you don't ...